NEW YORK – Zymo Research of Irvine, California, and Singapore-based BluMaiden Biosciences are teaming up to provide clinical trial analytics and reporting services based on the human microbiome to pharmaceutical companies.
The collaboration, announced on Tuesday, will make use of Zymo Research's expertise in sample prep and next-generation sequencing and BluMaiden's bioinformatics capabilities using its Keystone AI analytical platform.
The goal is to uncover clinical insights into health and disease from the human microbiome, including endpoint optimization, prediction of drug responders and non-responders, and patient enrichment and stratification.
The service will cover sample collection, nucleic acid purification, sequencing, bioinformatics data analysis, and clinical trial reporting and is designed to cover entire trial cohorts, various stages of trials, and different disease types and interventions.
The new service will be available in Europe and North America starting in the fourth quarter.